Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook

Amphastar Pharmaceuticals NASDAQ: AMPH executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.

MarketBeat • May 14, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 14, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Net revenues of $171.2 million for the three months ended March 31, 2026 GAAP net income of $6.4 million, or $0.14 per share, for the first quarter Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026.

Accesswire • May 7, 2026

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.7 per share. This compares to earnings of $0.74 per share a year ago.

Zacks Investment Research • May 7, 2026

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • May 8, 2026

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.

Accesswire • May 6, 2026

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the market closes on Thursday, May 7, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Accesswire • Apr 30, 2026

Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 29, 2026

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Apr 29, 2026